LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib

Lapatinib is a small molecule inhibitor of EGFR (HER1) and ERBB2 (HER2) receptors, which is used for treatment of advanced or metastatic breast cancer. To find the drug resistance mechanisms of treatment for EGFR/ERBB2 positive tumors, we analyzed the possible effects of lncRNAs. In this study, using CCLE (Cancer Cell Line Encyclopedia) database, we explored the relationship between the lncRNAs and Lapatinib sensitivity/resistance, and then validated those findings through in vitro experiments. We found that the expression of EGFR/ERBB2 and activation of ERBB pathway was significantly related to Lapatinib sensitivity. GO (Gene Oncology) analysis of top 10 pathways showed that the sensitivity of Lapatinib was positively correlated with cell keratin, epithelial differentiation, and cell-cell junction, while negatively correlated with signatures of extracellular matrix. Forty-four differentially expressed lncRNAs were found between the Lapatinib sensitive and resistant groups (fold-change > 1.5, P < 0.01). Gene set variation analysis (GSVA) was performed based on 44 lncRNAs and genes in the top 10 pathways. Five lncRNAs were identified as hub molecules. Co-expression network was constructed by more than five lncRNAs and 199 genes in the top 10 pathways, and three lncRNAs (GIHCG, SPINT1-AS1, and MAGI2-AS3) and 47 genes were identified as close-related molecules. The three lncRNAs in epithelium-derived cancers were differentially expressed between sensitive and resistant groups, but no significance was found in non-epithelium-derived cancer cells. Correlation analysis showed that SPINT1-AS1 (R = −0.715, P < 0.001) and GIHCG (R = 0.557, P = 0.013) were correlated with the IC50 of epithelium-derived cancer cells. In further experiments, GIHCG knockdown enhanced cancer cell susceptibility to Lapatinib, while high level of SPINT1-AS1 was a sensitive biomarker of NCI-N87 and MCF7 cancer cells to Lapatinib. In conclusions, lncRNAs GIHCG and SPINT1-AS1 were involved in regulating Lapatinib sensitivity. Up-regulation of GIHCG was a drug-resistant biomarker, while up-regulation of SPINT1-AS1 was a sensitive indicator.

[1]  K. Kakudo,et al.  Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway. , 2015, International journal of oncology.

[2]  Jing Han,et al.  SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88 , 2018, Journal of Experimental & Clinical Cancer Research.

[3]  Jianjian Zheng,et al.  lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141 , 2018, Cell Communication and Signaling.

[4]  Deepak K. Singh,et al.  MIR100 host gene-encoded lncRNAs regulate cell cycle by modulating the interaction between HuR and its target mRNAs , 2018, Nucleic acids research.

[5]  Lei Dong,et al.  RETRACTED ARTICLE: LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway , 2018, Cell cycle.

[6]  Yingyan Yu,et al.  Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer , 2018, Front. Pharmacol..

[7]  Jian Wen,et al.  A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer , 2018, Cellular Physiology and Biochemistry.

[8]  Peifeng Li,et al.  The Long Noncoding RNA D63785 Regulates Chemotherapy Sensitivity in Human Gastric Cancer by Targeting miR-422a , 2018, Molecular therapy. Nucleic acids.

[9]  Y. Zhang,et al.  Increased expression of antisense lncRNA SPINT1-AS1 predicts a poor prognosis in colorectal cancer and is negatively correlated with its sense transcript , 2018, OncoTargets and therapy.

[10]  Long Ma,et al.  Long noncoding RNA GIHCG enhanced tongue squamous cell carcinoma progression through regulating miR‐429 , 2018, Journal of cellular biochemistry.

[11]  N. Valeri,et al.  Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors , 2018, Front. Oncol..

[12]  W. Gong,et al.  LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer , 2018, Molecular Cancer.

[13]  Ming Wang,et al.  Activity dependent LoNA regulates translation by coordinating rRNA transcription and methylation , 2018, Nature Communications.

[14]  J. Rinn,et al.  An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance , 2018, Cell.

[15]  Joe W. Gray,et al.  Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes , 2018, Cell systems.

[16]  Xuedan Chen,et al.  LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein , 2018, Cell Death & Differentiation.

[17]  C. Cavaliere,et al.  Long noncoding RNA GIHCG is a potential diagnostic and prognostic biomarker and therapeutic target for renal cell carcinoma. , 2018, European review for medical and pharmacological sciences.

[18]  A. Tsatsakis,et al.  Role of the extracellular matrix in cancer‐associated epithelial to mesenchymal transition phenomenon , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  A. Pellat,et al.  Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology , 2018, Hepatology.

[20]  Joe Gray,et al.  Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound. , 2017, Cell reports.

[21]  S. Loibl,et al.  HER2-positive breast cancer , 2017, The Lancet.

[22]  Y. Mo,et al.  LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.

[23]  S. Gray,et al.  Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells , 2017, Cancers.

[24]  Liang Han,et al.  Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  L. Attardi,et al.  ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells , 2016, Oncogene.

[26]  A. Chinnaiyan,et al.  The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression , 2016, Nature Communications.

[27]  Joon-Oh Park,et al.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Jiamei Yang,et al.  Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429 , 2016, Journal of Molecular Medicine.

[29]  Hui Wang,et al.  Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer , 2016, Oncotarget.

[30]  Roberto Bianco,et al.  Mechanisms of lapatinib resistance in HER2-driven breast cancer. , 2015, Cancer treatment reviews.

[31]  J. Bourhis,et al.  Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Cole,et al.  CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. , 2015, Cancer research.

[33]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[34]  H. Harputluoglu,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO) , 2014, Journal of chemotherapy.

[35]  Y. Bang,et al.  Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. M. Lee,et al.  Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy , 2014, Oncogene.

[37]  M. Geng,et al.  A novel long non-coding RNA-ARA: adriamycin resistance-associated. , 2014, Biochemical pharmacology.

[38]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[39]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[40]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[41]  A. Martin,et al.  Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines , 2007, Cell proliferation.

[42]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[43]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[45]  D. Berney,et al.  Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.